BioCryst Pharmaceuticals to Present ORLADEYO Findings at 2025 Congress
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), a leader in innovations for hereditary angioedema (HAE), recently made headlines with their announcement regarding the upcoming presentations scheduled for the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) and World Allergy Organization (WAO) joint congress. This significant event will showcase five newly developed abstracts that delve into the clinical performance and real-world outcomes associated with their oral, once-daily treatment, ORLADEYO® (berotralstat).
Highlights of the APeX-P Pediatric Trial
Among the valuable presentations will be a late-breaking significant abstract from the pivotal APeX-P trial, focusing on how ORLADEYO impacts pediatric patients diagnosed with HAE, specifically those aged 2 to less than 12 years. This groundbreaking research reflects BioCryst's commitment to advancing HAE treatment and making a positive difference in patients' lives.
Event Details
The presentation will occur on March 2, with a time slot allocated from 9:45 to 10:45 a.m. PT in Hall A at the San Diego Convention Center. Attendees are encouraged to explore the learning opportunities and insights that these critical studies will provide in managing HAE effectively.
Abstracts to Be Presented
BioCryst will cover a variety of compelling topics, including:
- HAE Attack Rates in Pediatric Patients with Prophylactic Berotralstat: Results from APeX-P Interim Analysis; Poster #L55
- Real-World Attack Rates Before and After Berotralstat Initiation Among Patients with C1-Inhibitor Deficiency; Poster #603
- Real-World Attack Rates Before and After Berotralstat Initiation Among Patients without C1-Inhibitor Deficiency; Poster #607
- Patients’ Willingness to Change Long-Term Prophylaxis: Impact of Treatment Effectiveness; Poster #608
- Patient-Reported Impact of Berotralstat on HAE Attack Frequency; Poster #655
Understanding ORLADEYO® (berotralstat)
ORLADEYO is recognized as a pioneering oral therapy aimed specifically at preventing HAE attacks in both adults and pediatric patients, starting from the age of 12. With its unique mechanism of action, one daily capsule lowers plasma kallikrein activity, reducing HAE attacks significantly. It’s designed to provide relief to those who suffer from this challenging condition.
Safety and Usage Information
It is essential for healthcare providers and patients to understand the usage guidelines and safety information associated with ORLADEYO. The medication is specifically indicated for C1-inhibitor deficiencies and is not intended for treating acute HAE attacks. Moreover, specific dosage recommendations must be observed, especially concerning potential QT prolongation risks at higher doses.
The most frequently reported side effects include abdominal pain, vomiting, diarrhea, and more. To ensure safe usage, especially for those with hepatic impairments, a recommended lower dosage of 110 mg may apply.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals stands at the forefront of biotechnology innovation, dedicated to improving the lives of individuals affected by hereditary angioedema and various rare diseases. Their focus on structure-guided drug design allows the development of new small-molecule and protein therapeutics, making a significant impact on challenging health conditions. As they advance their pipeline, the company continues to solidify their position as a leader in the industry.
For more information and updates on ongoing research and treatments, please contact BioCryst Pharmaceuticals at 1-833-633-2279.
Frequently Asked Questions
What is ORLADEYO?
ORLADEYO is an oral, once-daily medication designed to prevent attacks in patients with hereditary angioedema.
What is the APeX-P trial?
The APeX-P trial evaluates the efficacy of ORLADEYO in pediatric patients diagnosed with HAE.
When will the presentations take place?
The presentations will occur on March 2, 2025, from 9:45 to 10:45 a.m. PT.
Where is the congress being held?
The event will be held at the San Diego Convention Center, California.
What should I know about the safety of ORLADEYO?
Patients should follow prescribed dosages and be aware of potential side effects, including abdominal pain and diarrhea. Monitoring is recommended for those with hepatic impairments.
